STOCK TITAN

Paysign Inc Stock Price, News & Analysis

PAYS Nasdaq

Welcome to our dedicated page for Paysign news (Ticker: PAYS), a resource for investors and traders seeking the latest updates and insights on Paysign stock.

Paysign Inc. (PAYS) delivers innovative prepaid card solutions and digital payment services for healthcare, corporate, and government sectors. This news hub provides investors with essential updates on the company’s financial performance and strategic direction.

Access real-time announcements including earnings reports, partnership developments, and product innovations. Our curated collection features regulatory filings, leadership changes, and market expansion updates critical for informed decision-making.

Discover comprehensive coverage of Paysign’s fintech advancements in patient affordability programs and integrated payment processing. Content spans merger activity, technology patents, and compliance updates, maintained for accuracy and relevance.

Bookmark this page for streamlined access to Paysign’s evolving financial narrative. Combine fundamental analysis with timely news to track the company’s position in competitive payment processing markets.

Rhea-AI Summary
Paysign (NASDAQ: PAYS) has successfully transitioned 123 out of 132 newly awarded plasma donation centers in just one week, significantly ahead of schedule. The remaining 9 centers are expected to go live in Q3 2025. This rapid implementation showcases Paysign's operational capabilities, platform scalability, and efficient execution. The company, which provides patient affordability solutions and payment processing services, completed the transition without disrupting center operations or donor services. CEO Mark Newcomer highlighted that this expansion represents a crucial return to revenue growth for their plasma business unit, complementing the strong performance of their patient affordability segment. The achievement demonstrates Paysign's ability to deliver reliable, scalable, and compliant payment solutions to plasma collection organizations while reinforcing their position in the healthcare financial services sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
none
-
Rhea-AI Summary
Paysign (NASDAQ: PAYS) has secured a major expansion by being awarded 132 established plasma donation centers through an extended partnership with a major plasma collection company. The transition will occur in phases, with 123 centers expected to be operational by Q2 2025 and the remaining 9 centers in Q3 2025. This expansion increases Paysign's plasma center network to over 615 locations across 18 plasma collection companies, boosting their U.S. market share to approximately 50%. The new centers are projected to achieve 80% of Paysign's average revenue per center within weeks of onboarding and reach full revenue contribution by Q1 2026. Notably, the company expects no significant increase in SG&A expenses for these additional centers, demonstrating strong operational leverage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
-
Rhea-AI Summary

Paysign (NASDAQ: PAYS), a provider of prepaid card programs, patient affordability solutions, digital banking services and integrated payment processing, has announced that CFO Jeff Baker will present at the MicroCap Rodeo Spring Conference in New York City. The presentation is scheduled for June 4, 2025, at 3:00 p.m. Eastern time and will be available via webcast. Management will also conduct one-on-one meetings with approved investors during the conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences
Rhea-AI Summary
Paysign (NASDAQ: PAYS) reported strong Q1 2025 financial results with total revenues of $18.60 million, up 41.0% year-over-year. Net income reached $2.59 million ($0.05 per diluted share), compared to $309,000 in Q1 2024. Adjusted EBITDA increased 193.3% to $4.96 million. The company's pharma patient affordability segment showed exceptional growth with revenue up 260.8%, adding 14 new programs for a total of 90 active programs. However, plasma revenue decreased 9.2% due to industry-wide oversupply. The company ended Q1 with $6.85 million in unrestricted cash, zero debt, and repurchased 100,000 shares. For full-year 2025, Paysign projects revenue of $72-74 million, with net income between $6-7 million and Adjusted EBITDA of $16-17 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary

Paysign (NASDAQ: PAYS), a provider of prepaid card programs, patient affordability solutions, digital banking services and integrated payment processing, has scheduled its first quarter 2025 earnings conference call for May 8, 2025, at 5:00 p.m. ET.

The company will host a conference call with both U.S. and international dial-in options. Financial professionals interested in participating in the Q&A session must register via email by May 2, 2025. A replay of the call will be available until August 8, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences earnings
-
Rhea-AI Summary

Paysign (NASDAQ: PAYS), a leading provider of prepaid card programs, patient affordability solutions, digital banking services and integrated payment processing, has announced its participation in the upcoming Ladenburg Thalmann Technology Innovation EXPO25.

The company's CFO, Jeff Baker, will deliver a presentation at the event, which is scheduled to take place in New York City on Wednesday, May 21, 2025. Interested investors can find additional information and registration details on the event's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
conferences
Rhea-AI Summary

Paysign (NASDAQ: PAYS) reported strong financial results for full-year 2024, with total revenues reaching $58.38 million, up 23.5% from 2023. The company's net income was $3.82 million ($0.07 per diluted share), compared to $6.46 million ($0.12 per diluted share) in 2023.

Key highlights include:

  • Adjusted EBITDA increased 43.3% to $9.62 million
  • Added 16 new plasma centers, ending with 480 centers
  • Added 33 net patient affordability programs, reaching 76 active programs
  • Patient affordability revenue grew 214.5% year-over-year
  • Ended 2024 with $10.77 million in unrestricted cash and zero debt

For Q4 2024, total revenues were $15.61 million, up 14.0% year-over-year. However, plasma revenue declined 6.2% to $10.80 million, while patient affordability revenue increased 156.5% to $4.31 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.47%
Tags
-
Rhea-AI Summary

Paysign (NASDAQ: PAYS) has acquired the assets of Gamma Innovation , strengthening its position in plasma donor and pharmaceutical patient engagement technologies. The acquisition includes key assets such as a donor engagement app and a specialized CRM platform designed for the blood and plasma collection industry.

As part of this strategic move, Michael Ngo, former Managing Member of Gamma, has been appointed as Paysign's Chief Innovation Officer. The company also welcomes key team members including Howard Steidle, Bei Xu, and Sam Wang, bringing expertise in business strategy, AI-driven analytics, and software development.

The integration aims to enhance Paysign's engagement, compensation, and resource management solutions across core markets, particularly strengthening relationships with plasma clients and bolstering patient affordability solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
management acquisition
-
Rhea-AI Summary

Paysign (NASDAQ: PAYS), a provider of prepaid card programs, patient affordability solutions, digital banking services and integrated payment processing, has scheduled its fourth quarter and full year 2024 earnings conference call for March 25, 2025, at 5:00 p.m. ET.

Financial professionals interested in participating in the Q&A session must register by emailing ir@paysign.com by March 21, 2025. A replay of the call will be available until June 25, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences earnings
Rhea-AI Summary

Paysign (NASDAQ: PAYS) has released its 2024 performance analysis for patient affordability solutions. The company's dynamic business rules feature, introduced in 2022, achieved significant results by saving pharmaceutical program sponsors over $100 million in 2024 through mitigating copay maximizer impacts with 97% accuracy.

Key 2024 achievements include: supporting 66+ retail and specialty pharmaceutical programs, assisting more than 500,000 unique patients (double compared to 2023), and contributing over $600 million toward prescription fulfillment expenses. The company's patient affordability platform offers configurable tools for copay assistance programs and pharmaceutical manufacturers' brand strategies, featuring real-time modifications to program criteria.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
none

FAQ

What is the current stock price of Paysign (PAYS)?

The current stock price of Paysign (PAYS) is $5.09 as of June 17, 2025.

What is the market cap of Paysign (PAYS)?

The market cap of Paysign (PAYS) is approximately 268.6M.
Paysign Inc

Nasdaq:PAYS

PAYS Rankings

PAYS Stock Data

268.65M
34.55M
37.81%
35.88%
1.07%
Software - Infrastructure
Services-business Services, Nec
Link
United States
HENDERSON